ISSN Print 2500–1094
ISSN Online 2542–1204
BIOMEDICAL JOURNAL OF PIROGOV UNIVERSITY (MOSCOW, RUSSIA)
Copyright: © 2025 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
ORIGINAL RESEARCH
PD1 expression in immune cells within the tumor microenvironment of patients with non-small cell and small cell lung cancer
About authors
The Laboratory of Molecular Therapy of Cancer, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia
Correspondence should be addressed: Evgenia S. Grigoryeva
Evgenia S. Grigoryeva
pereulok Kooperativnyj, 5, Tomsk, Russia; moc.liamg@se.aveyrogirg
About paper
Funding: the study was supported by the Russian Science Foundation (grant № 20-75-10033-П).
Author contribution: Kalinchuk AYu — literature search, obtaining and statistically processing the results, writing the article; Tsarenkova EA — obtaining and analyzing data; Loos DM — obtaining and analyzing data; Mokh AA — patients’ curation; Rodionov EO — patients’ curation; Miller SV — data collection; ES Grigoryeva — editing the article; Tashireva LA — study planning and supervision, analysis, and interpretation of results, writing the article.
Compliance with ethical standards: The study was approved by the Ethics Committee of the Tomsk National Research Medical Center Oncology Research Institute (protocol № 7, 25 August 2020; protocol № 18, 25 August 2023), conducted in accordance with federal laws of the Russian Federation and the 1964 Helsinki Declaration with all subsequent additions and amendments regulating scientific research on biomaterial obtained from humans. All participants signed informed voluntary consent to participate in the study.
Received: 2025-03-04
Accepted: 2025-03-17
Published online: 2025-03-24
|
Fig. 1. Tumor microenvironment of lung cancer. Multiplex image, 400x magnification
Fig. 2. The proportion of PD-1-positive CD8+ cytotoxic lymphocytes, CD20+ B-lymphocytes, FoxP3+ T-regulatory lymphocytes and CD163+ macrophages, and other PD-1-positive cells (without immunophenotype determination) in the tumor microenvironment of NSCLC and SCLC patients
Fig. 3. Comparison of the proportion of PD-1-expressing cells between NSCLC and SCLC patients
Table 1. Proportion of PD-1-Expressing Cells Among All Cells of the Studied Immunophenotype in Patients with Lung Cancer, Median (Q1–Q3)
Table 2. Univariate and multivariate regression analysis of the significance of clinicopathological parameters and immune cell populations in the duration of progression free survival in patients with lung cancer
Table 3. Univariate and multivariate regression analysis of the Influence of Clinicopathological Parameters and PD1-Expressing Immune Cell Populations on the Duration of Progression-Free Survival in Patients with Lung Cancer
